StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Analysts at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report issued on Wednesday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Shares of BTX stock opened at $1.53 on Wednesday. The company has a market cap of $90.00 million, a PE ratio of -0.67 and a beta of 4.61. The stock’s 50 day simple moving average is $1.77 and its two-hundred day simple moving average is $1.96. Brooklyn ImmunoTherapeutics has a 1 year low of $0.17 and a 1 year high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.